Undifferentiated Spondyloarthritis: a Longterm Followup
Overview
Authors
Affiliations
Objective: To analyze the longterm followup of a series of Brazilian patients with undifferentiated spondyloarthritis (uSpA).
Methods: Prospective study analyzing a group of 111 patients with the diagnosis of uSpA, fulfilling the European Spondylarthropathy Study Group and the Amor criteria, who were followed for 5 to 10 years in a single university referral center. Patients had their outcome analyzed at 5, 7, and 10 years.
Results: There was a predominance of men (81.1%), white ethnicity (78.4%), and positive HLA-B27 (61.3%), with a mean age at onset of 27.2 years. Twenty-seven patients presented development to ankylosing spondylitis (AS; 24.3%) and 3 to psoriatic arthritis (PsA; 2.7%), while 25 patients (22.5%) went into remission during the followup. Univariate logistic regression analysis revealed that ethnicity, HLA-B27, buttock pain, inflammatory low back pain, ankle involvement, grade I sacroiliitis at the beginning of the study, and the use of sulfasalazine were statistically associated with progression to AS. Multivariate logistic regression analysis revealed that HLA-B27 (p = 0.035, OR 6.720, 95% CI 11.45-39.43) and buttock pain (p = 0.009, OR 6.211, 95% CI 1.591-24.25) were statistically associated with progression to AS.
Conclusion: In a longterm followup of 111 Brazilian patients with uSpA, HLA-B27 and buttock pain were significant predictors of progression to a definite disease.
Poddubnyy D, Sieper J, Akar S, Munoz-Fernandez S, Haibel H, Hojnik M Rheumatology (Oxford). 2021; 61(8):3299-3308.
PMID: 34897381 PMC: 9348765. DOI: 10.1093/rheumatology/keab901.
Pina Vegas L, Sbidian E, Wendling D, Goupille P, Ferkal S, Le Corvoisier P Rheumatology (Oxford). 2021; 61(4):1487-1495.
PMID: 34270707 PMC: 8996779. DOI: 10.1093/rheumatology/keab565.
Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis.
Li Z, Wu X, Leo P, De Guzman E, Akkoc N, Breban M Ann Rheum Dis. 2021; 80(9):1168-1174.
PMID: 34161253 PMC: 8364478. DOI: 10.1136/annrheumdis-2020-219446.
Cengiz M, Ataman S, Sunar I, Yalcin A, Yilmaz G, Elhan A Rheumatol Int. 2021; 42(3):495-502.
PMID: 33675418 DOI: 10.1007/s00296-021-04807-5.
The role of ixekizumab in non-radiographic axial spondyloarthritis.
Koo B, Kim T Ther Adv Musculoskelet Dis. 2021; 13:1759720X20986734.
PMID: 33488787 PMC: 7809523. DOI: 10.1177/1759720X20986734.